Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2011

01.11.2011 | Brief Report

What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?

verfasst von: Dora Il’yasova, Sharareh Siamakpour-Reihani, Igor Akushevich, Lucy Akushevich, Neil Spector, Joellen Schildkraut

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory Breast Carcinoma (IBC), the most aggressive type of breast tumor with unique clinicopathological presentation, is hypothesized to have distinct etiology with a socioeconomic status (SES) component. Using the Surveillance, Epidemiology and End Results (SEER) Program data for 2004–2007, we compare incidence rates of IBC to non-inflammatory locally advanced breast cancer (LABC) among racial/ethnic groups with different SES. The analysis includes women 20–84 years of age. To examine evidence for the distinct etiology of IBC, we analyzed age-distribution patterns of IBC and non-inflammatory LABC, using a mathematical carcinogenesis model. Based on the Collaborative Staging Extension codes, 2,942 incident IBC cases (codes 71 and 73) and 5,721 non-inflammatory LABC cases (codes 40–62) were identified during the four-year study period. Age-adjusted rates of IBC among non-Hispanic White and Hispanic women were similar (2.5/100,000 in both groups). Similar rates were also found in non-inflammatory LABC in these two groups (4.8/100,000 and 4.2/100,000, respectively). In African-American women, the IBC (3.91/100,000) and non-inflammatory LABC (8.47/100,000) rates were greater compared with other ethnic/racial sub-groups. However, the ratio of rates of IBC/non-inflammatory LABC was similar among all the racial/ethnic groups, suggesting that African-American women are susceptible to aggressive breast tumors in general but not specifically to IBC. The mathematical model successfully predicted the observed age-specific rates of both examined breast tumors and revealed distinct patterns. IBC rates increased until age 65 and then slightly decreased, whereas non-inflammatory LABC rates steadily increased throughout the entire age interval. The number of critical transition carcinogenesis stages (m-stages) predicted by the model were 6.3 and 8.5 for IBC and non-inflammatory LABC, respectively, supporting different etiologies of these breast tumors.
Literatur
1.
Zurück zum Zitat Robertson FM, Bondy M, Yang W et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60(6):351–375PubMedCrossRef Robertson FM, Bondy M, Yang W et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60(6):351–375PubMedCrossRef
2.
Zurück zum Zitat Cristofanilli M, Buchholz TA (2010) Proceedings of the first international inflammatory breast cancer conference. Cancer 116(11 Suppl):2729PubMedCrossRef Cristofanilli M, Buchholz TA (2010) Proceedings of the first international inflammatory breast cancer conference. Cancer 116(11 Suppl):2729PubMedCrossRef
3.
Zurück zum Zitat Dawood S, Merajver SD, Viens P et al (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22(3):515–523PubMedCrossRef Dawood S, Merajver SD, Viens P et al (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22(3):515–523PubMedCrossRef
4.
Zurück zum Zitat Anderson WF, Chu KC, Chang S (2003) Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 21(12):2254–2259PubMedCrossRef Anderson WF, Chu KC, Chang S (2003) Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 21(12):2254–2259PubMedCrossRef
5.
Zurück zum Zitat Boussen H, Bouzaiene H, Ben JH et al (2010) Inflammatory breast cancer in Tunisia: epidemiological and clinical trends. Cancer 116(11 Suppl):2730–2735PubMedCrossRef Boussen H, Bouzaiene H, Ben JH et al (2010) Inflammatory breast cancer in Tunisia: epidemiological and clinical trends. Cancer 116(11 Suppl):2730–2735PubMedCrossRef
6.
Zurück zum Zitat Boussen H, Bouzaiene H, Ben JH, Gamoudi A, Benna F, Rahal K (2008) Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Semin Oncol 35(1):17–24PubMedCrossRef Boussen H, Bouzaiene H, Ben JH, Gamoudi A, Benna F, Rahal K (2008) Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Semin Oncol 35(1):17–24PubMedCrossRef
7.
Zurück zum Zitat Labidi SI, Mrad K, Mezlini A et al (2008) Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol 19(3):473–480PubMedCrossRef Labidi SI, Mrad K, Mezlini A et al (2008) Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol 19(3):473–480PubMedCrossRef
8.
Zurück zum Zitat Ionta MT, Atzori F, Massidda B (2010) Inflammatory breast cancer in Italy: epidemiological and clinical aspects. Cancer 116(11 Suppl):2736–2740PubMedCrossRef Ionta MT, Atzori F, Massidda B (2010) Inflammatory breast cancer in Italy: epidemiological and clinical aspects. Cancer 116(11 Suppl):2736–2740PubMedCrossRef
9.
Zurück zum Zitat Wingo PA, Jamison PM, Young JL, Gargiullo P (2004) Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control 15(3):321–328PubMedCrossRef Wingo PA, Jamison PM, Young JL, Gargiullo P (2004) Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control 15(3):321–328PubMedCrossRef
10.
Zurück zum Zitat Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975PubMedCrossRef Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975PubMedCrossRef
11.
Zurück zum Zitat Levine PH, Veneroso C (2008) The epidemiology of inflammatory breast cancer. Semin Oncol 35(1):11–16PubMedCrossRef Levine PH, Veneroso C (2008) The epidemiology of inflammatory breast cancer. Semin Oncol 35(1):11–16PubMedCrossRef
12.
Zurück zum Zitat Dawood S, Ueno NT, Valero V et al (2011) Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9):1819–1826PubMedCrossRef Dawood S, Ueno NT, Valero V et al (2011) Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9):1819–1826PubMedCrossRef
13.
Zurück zum Zitat Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD (1998) Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 82(12):2366–2372PubMedCrossRef Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD (1998) Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 82(12):2366–2372PubMedCrossRef
14.
Zurück zum Zitat Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23PubMed Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23PubMed
15.
Zurück zum Zitat Baquet CR, Commiskey P (2000) Socioeconomic factors and breast carcinoma in multicultural women. Cancer 88(5 Suppl):1256–1264PubMedCrossRef Baquet CR, Commiskey P (2000) Socioeconomic factors and breast carcinoma in multicultural women. Cancer 88(5 Suppl):1256–1264PubMedCrossRef
16.
Zurück zum Zitat Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA (2010) Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat 121(2):281–292PubMedCrossRef Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA (2010) Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat 121(2):281–292PubMedCrossRef
17.
Zurück zum Zitat The US Census Bureau (2010) About poverty: highlights for the calendar year of 2009. The US Census Bureau, Washington, DC The US Census Bureau (2010) About poverty: highlights for the calendar year of 2009. The US Census Bureau, Washington, DC
18.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program (2010). SEER*Stat database: SEER 17 registeries research data and Hurricane Katrina impacted Louisiana cases. www.seer.cancer.gov Surveillance, Epidemiology, and End Results (SEER) Program (2010). SEER*Stat database: SEER 17 registeries research data and Hurricane Katrina impacted Louisiana cases. www.​seer.​cancer.​gov
19.
Zurück zum Zitat Taylor SH, Walters R (2010) Potential impact of tumor registry rule changes for recording inflammatory breast cancer. Cancer 116(11 Suppl):2745–2747PubMedCrossRef Taylor SH, Walters R (2010) Potential impact of tumor registry rule changes for recording inflammatory breast cancer. Cancer 116(11 Suppl):2745–2747PubMedCrossRef
20.
Zurück zum Zitat Hankey BF, Ries LA, Edwards BK (1999) The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 8(12):1117–1121PubMed Hankey BF, Ries LA, Edwards BK (1999) The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 8(12):1117–1121PubMed
21.
Zurück zum Zitat Collaborative Staging Task Force of the American Joint Committee on Cancer (2007) Collaborative staging manual and coding instructions, version 01.04.00. U.S. Department of Health and Human Services, Washington DC Collaborative Staging Task Force of the American Joint Committee on Cancer (2007) Collaborative staging manual and coding instructions, version 01.04.00. U.S. Department of Health and Human Services, Washington DC
22.
Zurück zum Zitat Manton KG, Akushevich I, Kravchenko J (2009) Cancer mortality and morbidity patterns in the U.S. population: an interdisciplinary approach. Springer, New YorkCrossRef Manton KG, Akushevich I, Kravchenko J (2009) Cancer mortality and morbidity patterns in the U.S. population: an interdisciplinary approach. Springer, New YorkCrossRef
23.
Zurück zum Zitat Kravchenko J, Akushevich I, Seewaldt VL, Abernethy AP, Lyerly HK (2011) Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. Breast Cancer Res Treat 128(2):483–493 Kravchenko J, Akushevich I, Seewaldt VL, Abernethy AP, Lyerly HK (2011) Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. Breast Cancer Res Treat 128(2):483–493
24.
Zurück zum Zitat Manton KG, Akushevich I, Kulminski A (2008) Human mortality at extreme ages: data from the NLTCS and linked Medicare records. Math Popul Stud 15(3):137–159CrossRef Manton KG, Akushevich I, Kulminski A (2008) Human mortality at extreme ages: data from the NLTCS and linked Medicare records. Math Popul Stud 15(3):137–159CrossRef
25.
Zurück zum Zitat Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285PubMedCrossRef Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285PubMedCrossRef
Metadaten
Titel
What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?
verfasst von
Dora Il’yasova
Sharareh Siamakpour-Reihani
Igor Akushevich
Lucy Akushevich
Neil Spector
Joellen Schildkraut
Publikationsdatum
01.11.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1719-4

Weitere Artikel der Ausgabe 2/2011

Breast Cancer Research and Treatment 2/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.